Neonatal Sepsis

WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis (“EOS”). This represents the company’s 80th system designed to treat musculoskeletal issues in children. VerteGlide is a guided growth technology designed for children with Early Onset Scoliosis, a severe and sometimes life-threatening condition affecting kids under the age of 10, who often suffer from pulmonary and digestive dysfunction because of the deformity. VerteGlide represents the second in a series of technologies OrthoPediatrics is developing to address the challenges of this special group of children suffering from debilitating and life-threatening consequences of Early Onset Scoliosis. With its unique design, the VerteGlide Spinal Growth Guidance System is designed to allow for deformity correction and minimize repeat surgeries needed until skeletal maturity. With the recent FDA clearance of this device, the Company is preparing for a limited launch and expects to be doing initial surgeries with select children's centers during summer of this year. Dr. Richard McCarthy, a pediatric orthopedic spine surgeon in Louisville, Kentucky is a pioneer in the field of growth guidance in scoliosis surgery; he and Dr. Scott Luhmann of St. Louis have been instrumental in partnering with the Company on the design and development of the system. McCarthy shared that "VerteGlide marks a breakthrough in technology for children." OrthoPediatrics Scoliosis division President, Greg Odle commented “We are excited to introduce another new product to treat children with EOS. The team has been working with key opinion leaders from the surgeon community to identify new technologies that will help this particularly vulnerable patient population. VerteGlide’s launch represents our commitment to treating the entire disease state of scoliosis.” CEO, David Bailey echoed those comments, saying “I’m incredibly proud of the Engineering team and the work the business teams have done to bring this product to market. It feels like we are making meaningful progress in providing healthcare professionals innovative treatment options for the patients they serve.” The VerteGlide Spinal Growth Guidance System is made possible with the Shilla™ technology licensed from Medtronic. About OrthoPediatrics Corp.Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com. Investor ContactPhilip Trip TaylorGilmartin Groupphilip@gilmartinir.com415-937-5406

LEXINGTON, Mass., Jan. 9, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services to fund a phase 2 study in patients with sepsis to assess the safety and enable dose selection of LEUKINE (sargramostim, rhu GM-CSF). The partners also will evaluate monocyte human leukocyte antigen-DR (mHLA-DR) and other biomarkers of immune status that could enable more precise identification of patients with sepsis who could benefit from LEUKINE treatment in addition to standard of care. Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection, characterized by altered immune homeostasis.1 It represents a critical unmet public health need urgently requiring safe and effective therapeutics guided by biomarkers to enable precise treatment approaches to reduce morbidity and mortality.2,3 In 2017, 1.7 million sepsis cases were reported in the US and 48.9 million cases were reported globally resulting in 11 million deaths.21 Since much of the morbidity and mortality from chemical, biological, radiological and nuclear (CBRN) threats is due to sepsis, the availability of a host-directed therapy to treat sepsis utilizing validated biomarkers to inform treatment would greatly enhance health security. Leukine is currently held for use by ASPR-Strategic National Stockpile (SNS) for the treatment of hematopoietic acute radiation syndrome (H-ARS) as a host-directed therapy. The PTx-BARDA partnership seeks to enhance patient care through restoration of immune homeostasis in patients with sepsis exhibiting a persistent immune suppressed state. Research shows that patients with sepsis with persistent immune suppression are unable to mount a sufficient immune response and experience significant mortality.2,4,5 The clinical study will further evaluate the safety of LEUKINE in these critically ill patients and seeks to confirm the utility of mHLA-DR as a marker to identify sepsis-associated immune dysregulation.2,6-10 Additional promising biomarkers of immune status in patients with sepsis also will be evaluated. Under a prior collaboration, BARDA and PTx supported the establishment of a Laboratory Developed Test (LDT) for mHLA-DR, which will be utilized in this collaboration. "We are grateful to BARDA for their support of this program, which has the potential to advance medical care for patients with sepsis by evaluating potential tools for measuring immune status to inform targeted immunomodulatory therapy," stated John L. McManus, President, Health Security and Critical Care of Partner Therapeutics, Inc. In small randomized clinical trials in critically ill patients with severe sepsis or septic shock, LEUKINE has been shown to promote immune homeostasis, as measured by a rapid and sustained improvement in mHLA-DR expression, as well as other markers of innate and adaptive immune function.7,11-16 The observed changes in immune status were accompanied by improved clinical outcomes including 28-day survival and resolution of infection. GM-CSF helps maintain immune homeostasis via innate and adaptive responses, and promotes tissue repair mechanisms.2,7,17 While classically known for promoting differentiation of bone marrow (BM) precursor cells, and stimulating proliferation, differentiation, and maturation of myeloid cells, GM-CSF also induces mHLA-DR and plays important roles in antigen presentation, T-cell activation, and myeloid cell survival and function.7,17-19 HLA-DR is part of the heterodimeric major histocompatibility complex class II (MHC II) on monocytes and is a measure of the cells' capacity for antigen-presentation. MHC II regulates monocytes' crosstalk with T helper cells, enabling the activation of the adaptive immune system.4,20 This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50124C00061. REFERENCES Singer M et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-810. doi: 10.1001/jama.2016.0287 Cajander S et al. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. Lancet Resp Med. 2023;12(4):305-322. doi: 10.1016/S2213-2600(23)00330-2 Shankar-Hari M et al. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. Lancet Resp Med. 2024;12(4):323 – 336. doi: 10.1016/S2213-2600(23)00468-X Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018 Feb;14(2):121-137. doi: 10.1038/NRNEPH.2017.165 Lindell RB, Meyer NJ. Charting a course for precision therapy trials in sepsis. Lancet Respir Med. 2024 Apr;12(4):265-267. doi: 10.1016/S2213-2600(24)00070-5 Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard A-L, Thizy H, Bienvenu J, Gueyffier F, Vanhems P. 2006. "Persisting Low Monocyte Human Leukocyte Antigen-DR Expression Predicts Mortality in Septic Shock." Intensive Care Medicine 32 (8): 1175–83. doi: 10.1007/S00134-006-0204-8 Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, et al. 2009. "Granulocyte–Macrophage Colony-Stimulating Factor to Reverse Sepsis-Associated Immunosuppression." American Journal of Respiratory and Critical Care Medicine 180 (7): 640–48. doi: 10.1164/RCCM.200903-0363OC Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol. 2013 Aug;25(4):477-83. doi: 10.1016/J.COI.2013.05.006 Morris AC, Datta D, Shankar-Hari M, Stephen J, Weir CJ, Rennie J, Antonelli J, et al. 2018. "Cell-Surface Signatures of Immune Dysfunction Risk-Stratify Critically Ill Patients: INFECT Study." Intensive Care Medicine 44 (5): 627–35. doi: 10.1007/S00134-018-5247-0 Tremblay JA, Peron F, Kreitmann L, Textoris J, Brengel-Pesce K, Lukaszewicz AC, Quemeneur L, Vedrine C, Tan LK, Venet F, Rimmele T, Monneret G, et al. A stratification strategy to predict secondary infection in critical illness-induced immune dysfunction: the REALIST score. Annals of Intensive Care 2022 12:76. doi: 10.1186/S13613-022-01051-3 Rosenbloom AJ, Linden PK, Dorrance A, Penkosky N, Cohen-Melamed MH, Pinsky MR. 2005. "Effect of Granulocyte-Monocyte Colony-Stimulating Factor Therapy on Leukocyte Function and Clearance of Serious Infection in Nonneutropenic Patients." CHEST 127 (6): 2139–50. doi: 10.1378/CHEST.127.6.2139. Hall, MW., Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, Carcillo JA. 2011. "Immunoparalysis and Nosocomial Infection in Children with Multiple Organ Dysfunction Syndrome." Intensive Care Medicine 37 (3): 525–32. doi: 10.1007/S00134-010-2088-X Spies C, Luetz A, Lachmann G, Renius M, von Haefen C, Wernecke K-D, Bahra M, Schiemann A, Paupers P, Meisel C. 2015. "Influence of Granulocyte-Macrophage Colony-Stimulating Factor or Influenza Vaccination on HLA-DR, Infection and Delirium Days in Immunosuppressed Surgical Patients: Double Blind, Randomised Controlled Trial." Edited by Sachin Yende. PLOS ONE 10 (12): e0144003. doi: 10.1371/JOURNAL.PONE.0144003 Pinder EM, Rostron Aj, Hellyer TP, Ruchaud-Sparagano M-H, Scott J, Macfarlane JG, Wiscombe S, et al. 2018. "Randomised Controlled Trial of GM-CSF in Critically Ill Patients with Impaired Neutrophil Phagocytosis." Thorax 73 (10): 918–25. doi: 10.1136/THORAXJNL-2017-211323 Hassan SA, Alamed Z, Syed U, Nadeem MT, Khushdil A. The Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Neutropenia and Mortality in Neonatal Sepsis. Pak Armed Forces Med J 2023; 73(6): 1644-1647. doi: 10.51253/PAFMJ.V73I6.7456 Vacheron CH, Lepape A, Venet F, Monneret G, Gueyffier F, Boutitie F, Vallin H, Schwebel C, Maucort-Boulch D, Friggeri A; GRID Study Group. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: The GRID randomized controlled trial. J Crit Care. 2023 Dec;78:154330. doi: 10.1016/J.JCRC.2023.154330 Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. Immunity. 2019 Apr 16;50(4):796-811. doi: 10.1016/j.immuni.2019.03.022 Mathias B, Szpila BE, Moore FA, Efron PA, Moldawer LL. 2015. "A Review of GM-CSF Therapy in Sepsis." Medicine 94 (50): e2044. doi: 10.1097/MD.0000000000002044 Joshi I et al. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis. Front Immunol. 2023;14:1130214. doi: 10.3389/fimmu.2023.1130214 Shi Y, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 2006;16(2):126-133. doi: 10.1038/sj.cr.7310017 Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7 ABOUT LEUKINE LEUKINE (sargramostim) is a glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in yeast. The product is commercially available in the United States and accessible through a named patient program operated by Tanner Pharma Group outside of the United States. LEUKINE is indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older. For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). Important Safety Information for LEUKINE (sargramostim) Contraindications Do not administer LEUKINE to patients with a history of serious allergic reaction, including anaphylaxis, to human granulocyte-macrophage colony-stimulating factor, sargramostim, yeast-derived products, or any other component of LEUKINE. Warnings and Precautions Serious hypersensitivity reactions, including anaphylactic reactions, have been reported with LEUKINE. If a serious allergic or anaphylactic reaction occurs, immediately discontinue LEUKINE therapy, and institute medical management. Discontinue LEUKINE permanently for patients with serious allergic reactions. LEUKINE can cause infusion-related reactions that may be characterized by respiratory distress, hypoxia, flushing, hypotension, syncope, and/or tachycardia. Observe closely during infusion, particularly in patients with preexisting lung disease; dose adjustment or discontinuation may be needed. LEUKINE should not be administered simultaneously with or within 24 hours preceding cytotoxic chemotherapy or radiotherapy or within 24 hours following chemotherapy. Edema, capillary leak syndrome, and pleural or pericardial effusions have been reported in patients after LEUKINE administration. LEUKINE should be used with caution in patients with preexisting fluid retention, pulmonary infiltrates, or congestive heart failure. Such patients should be monitored. Supraventricular arrhythmia has been reported in uncontrolled studies during LEUKINE administration, particularly in patients with a history of cardiac arrhythmia. Use LEUKINE with caution in patients with preexisting cardiac disease. If absolute neutrophil count (ANC) > 20,000 cells/mm3 or if white blood cell (WBC) counts > 50,000/mm3, LEUKINE administration should be interrupted, or the dose reduced by half. Monitor complete blood counts (CBC) with differential twice per week. Discontinue LEUKINE therapy if tumor progression, particularly in myeloid malignancies, is detected during LEUKINE treatment. Treatment with LEUKINE may induce neutralizing anti-drug antibodies. Use LEUKINE for the shortest duration needed. Avoid administration of solutions containing benzyl alcohol (including LEUKINE for injection reconstituted with Bacteriostatic Water for Injection, USP [0.9 % benzyl alcohol]) to neonates and low birth weight infants. Drug Interactions Avoid the concomitant use of LEUKINE and products that induce myeloproliferation. Monitor for clinical and laboratory signs of excess myeloproliferative effects. Adverse Reactions Adverse events occurring in >10% of patients receiving LEUKINE in controlled clinical trials and reported at a higher frequency than in placebo patients are: In recipients of autologous bone marrow transplantation (BMT)–asthenia, malaise, diarrhea, rash, peripheral edema, urinary tract disorder In recipients of allogeneic BMT–abdominal pain, chills, chest pain, diarrhea, nausea, vomiting, hematemesis, dysphagia, GI hemorrhage, pruritus, bone pain, arthralgia, eye hemorrhage, hypertension, tachycardia, bilirubinemia, hyperglycemia, increased creatinine, hypomagnesemia, edema, pharyngitis, epistaxis, dyspnea, insomnia, anxiety, high glucose, low albumin In patients with AML–fever, weight loss, nausea, vomiting, anorexia, skin reactions, metabolic laboratory abnormalities, edema ABOUT PARTNER THERAPEUTICS Partner Therapeutics, Inc. (PTx), an integrated biotechnology company, focuses on development and commercialization of late-stage therapeutics to improve health outcomes in treatment of cancer and other serious diseases. The company believes in delivering products and supporting medical teams with the purpose of achieving superior outcomes for patients and their families. Visit MEDIA CONTACT [email protected] SOURCE Partner Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C. Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute. Apart from pneumonia, their work focused on maternal and children’s vaccines including influenza, respiratory syncytial virus (RSV), typhoid, and Group B streptococcus (GBS). The evidence produced by these two awardees has and continues to inform the World Health Organization’s recommendations for vaccines. Klugman and Madhi’s research has helped pave the way for the introduction of lifesaving vaccines in public immunization programs – including the pneumococcal conjugate vaccine where their findings were pivotal in influencing vaccination policy in many LMICs. “I am honored to award the Sabin Gold Medal to Dr. Klugman and Dr. Madhi for their extraordinary work on vaccines that have saved lives in communities most in need of these interventions,” says Amy Finan, Sabin’s chief executive officer. “Their pneumonia research has been particularly transformative in shaping our understanding of the disease and strengthening global health strategies to protect children from this vaccine-preventable disease.” Fueled by an early interest in science as a child in South Africa -- in part due to a physician father – Klugman holds both a medical as well as a science doctorate degree from Wits University and was the first student in the school’s history to obtain them simultaneously. He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist. Klugman is widely known for his work on pneumonia, which still kills a child under five every 43 seconds, many in the world’s poorest countries. As the director of the pneumonia program at the Seattle-based Bill and Melinda Gates Foundation, Klugman orchestrates strategic initiatives aimed at reducing deaths from pneumonia, RSV, neonatal sepsis, and meningitis. He has authored hundreds of publications that have been cited over 50,000 times to date and has been elected to the National Academy of Medicine in the United States. Klugman is also a professor emeritus of global health at Atlanta’s Emory University. His scientific achievements aside, Klugman has long championed the need for the world’s poorest children to have equitable access to vaccines. While in South Africa he joined in Wits University’s struggle to allow access to the institution for all students. “It is absolutely wonderful to be receiving this award, especially together with Shabir,” he says. “When I look down the list of previous awardees, I recognize the great majority of them, and it is extraordinary to now be numbered among them.” With a career spanning more than 25 years, Madhi, also from South Africa, is a trained pediatrician whose research continues to be instrumental in prioritizing the rollout of vital vaccines and guiding global public health policies. At Wits University, he led clinical trials focused on respiratory and meningeal pathogens, including vaccines targeted at pregnant women and their unborn babies. Madhi led the first study showing that a rotavirus vaccine could significantly prevent severe diarrhea during the first year of life in African infants. That research served as a key piece of evidence for the WHO’s recommendation of universal rotavirus vaccination. In addition, he also led the first two COVID-19 vaccine trials in Africa, and a number of COVID-19 epidemiology studies which led to the first evidence suggesting that infection-induced immunity and vaccinations played a role in reducing severity of disease. Madhi heads South Africa’s widely respected South African Medical Research Council (SAMRC) Vaccines and Infectious Diseases Analytics Research Unit (Wits VIDA) and is a professor of vaccinology at Wits. He too has co-authored hundreds of publications which have been cited over 59,000 times. Madhi is a recipient of numerous lifetime achievement awards in South Africa, as well being bestowed an Honorary Commander of the Order of the British Empire (CBE) from the British Government for his services to science and public health in a global pandemic. “It is really humbling for me to be acknowledged for my contributions in the field of vaccinology along with those who have received the Gold Medal award,” says Madhi. “It makes me realize that the work my team and I have done is acknowledged by my peers as being of substance. Most significantly, we contributed to protecting lives in those settings where a majority of death and suffering occurs, and that is in LMICs.” Sabin’s 2024 Rising Star Nicole Basta, an associate professor at Canada’s McGill University and Canada Research Chair in Infectious Disease Prevention, has led numerous studies to evaluate the impact of vaccines and vaccination programs for a number of globally challenging viral and bacterial diseases, including COVID-19, meningococcal disease, influenza, and HPV. Inspired by her parents’ emphasis on the importance of education, Basta is a first-generation college graduate who earned an undergraduate degree at Princeton University and graduate degrees at the University of Cambridge and the University of Washington. She has distinguished herself as a prolific researcher with a focus on assessing the impact of vaccination programs and increasing vaccine awareness, acceptance, and uptake. She designed and led studies to evaluate the impact of the meningococcal A vaccine MenAfriVac in Mali and the meningococcal B vaccine Bexsero in the US, both of which contributed to better understanding about how to best implement vaccination programs. In 2020, she and a colleague developed an interactive online COVID-19 vaccine tracker, providing real-time updates to millions of users around the world on the pandemic vaccine development progress. “Prof. Basta’s impactful and policy-shaping epidemiological research benefits from her ability to make it accessible and useful to the global health community. The COVID-19 vaccine tool is one such instance,” says Finan. “Those achievements alone would make her deserving of the Rising Star but there’s more: she also demonstrates a deep commitment to mentoring the next generation of public health researchers through her research group which is exactly the kind of emerging leader we need.” Once an infectious diseases outbreak investigator with the Florida Department of Health, Basta has first-hand knowledge that scientific research needs to be understood and adopted beyond the confines of academia. She works with policy makers and public health agencies and organizations to translate research findings into actionable strategies for disease prevention and control. “It’s truly an honor to receive the 2024 Rising Star Award from the Sabin Vaccine Institute, especially since I am deeply committed to ensuring that we have the evidence we need to demonstrate the importance of vaccination and increase access and uptake,” says Basta. “This recognition is also a testament to the outstanding collaborators and trainees I have had the privilege to work with and it motivates us to continue to make a difference in the years ahead.” The Gold Medal is Sabin’s highest scientific honor. It has been given annually for more than three decades to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Bill Foege, Anne Gershon, Stanley Plotkin, and Kathrin Jansen. Sabin’s Rising Star award was created in 2020 to encourage and recognize the next generation of vaccine and immunization leaders. About the Sabin Vaccine Institute The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit and follow us on Twitter, @SabinVaccine. Media Contact: Monika Guttman Senior Media Relations Specialist Sabin Vaccine Institute +1 (202) 662-1841 press@sabin.org A photo accompanying this announcement is available at 2024 Albert B. Sabin Gold Medal and 2024 Sabin Rising Star Award Presentations Dr. Keith Klugman (left) and Dr. Shabir Madhi (right) were presented the 2024 Albert B. Sabin Gold Medal and Prof. Nicole Basta (center) received the 2024 Sabin Rising Star Award from the Sabin Vaccine Institute at the National Academy of Sciences in Washington, D.C.